Gemzar News and Research

RSS
U.S. Court upholds validity of Eli Lilly's Gemzar compound patent

U.S. Court upholds validity of Eli Lilly's Gemzar compound patent

Teva Pharmaceutical Industries' Gemzar patent litigation: U.S. court issues decision

Teva Pharmaceutical Industries' Gemzar patent litigation: U.S. court issues decision

Eli Lilly provides financial guidance for 2010

Eli Lilly provides financial guidance for 2010

Positive data from Onconova Therapeutics' ON 01910.Na trial for advanced MDS

Positive data from Onconova Therapeutics' ON 01910.Na trial for advanced MDS

Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported

Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported

Clavis Pharma signs drug development and commercialisation agreement with Clovis Oncology

Clavis Pharma signs drug development and commercialisation agreement with Clovis Oncology

Press conference highlights emerging treatments in pancreatic cancer

Press conference highlights emerging treatments in pancreatic cancer

Seattle Genetics reports its third-quarter financial results

Seattle Genetics reports its third-quarter financial results

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Huachansu may slow cancer progression

Huachansu may slow cancer progression

U.S. District Court rules against Lilly regarding Gemzar patent

U.S. District Court rules against Lilly regarding Gemzar patent

Array Biopharma reports Q4 and full year 2009 financials

Array Biopharma reports Q4 and full year 2009 financials

Discovery of critical marker of response to gemcitabine in pancreatic cancer

Discovery of critical marker of response to gemcitabine in pancreatic cancer

Scientists shed new light on why pancreatic cancer drugs can fail

Scientists shed new light on why pancreatic cancer drugs can fail

Variations in mismatch repair genes predict prognosis in pancreatic cancer

Variations in mismatch repair genes predict prognosis in pancreatic cancer

Pharmion and MethylGene announce orphan drug designation for treatment of Hodgkin's lymphoma

Pharmion and MethylGene announce orphan drug designation for treatment of Hodgkin's lymphoma

Studies try to shed light on impact of race

Studies try to shed light on impact of race

Massive gene screening points way to more effective chemotherapy

Massive gene screening points way to more effective chemotherapy

FDA gives the green light for Gemzar to treat recurrent ovarian cancer

FDA gives the green light for Gemzar to treat recurrent ovarian cancer

FDA approval for Gemzar for ovarian cancer

FDA approval for Gemzar for ovarian cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.